News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gilead Sciences, Inc. (GILD)'s Solvadi Strikes Again: $1,000 A Pill Rattles Medicaid Programs



4/29/2014 8:25:20 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Medicaid health insurance programs for the poor are grappling with how to pay for the costly Hepatitis C treatment Sovaldi, which costs $1,000 a pill and is running up a huge tab for states already grappling with myriad health and general budgetary issues. The costs are hitting Medicaid programs extraordinarily hard because the population of patients in need of Sovaldi tend to have low incomes and wouldn’t be able to afford it without the government insurance. Sovaldi, developed by Gilead Sciences GILD +0.89% (GILD), has been hailed for its effectiveness in treating Hepatitis C, a disease that effects more than 3 million people in the U.S.

Help employers find you! Check out all the jobs and post your resume.

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES